Spots Global Cancer Trial Database for ficlatuzumab
Every month we try and update this database with for ficlatuzumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer | NCT03316599 | Pancreatic Canc... | Gemcitabine Nab-paclitaxel Ficlatuzumab | 18 Years - | Dana-Farber Cancer Institute | |
| Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma | NCT03422536 | Head and Neck B... Recurrent Head ... Recurrent Oroph... Squamous Cell C... Stage IV Squamo... Stage IV Squamo... Stage IV Nasoph... Stage IV Oropha... Stage IVA Lip a... Stage IVA Nasal... Stage IVA Nasop... Stage IVA Oroph... Stage IVB Lip a... Stage IVB Nasal... Stage IVB Nasop... Stage IVB Oroph... Stage IVC Lip a... Stage IVC Nasal... Stage IVC Nasop... Stage IVC Oroph... Head and Neck C... Oropharyngeal C... HNSCC Stage IV Lip an... | Cetuximab Ficlatuzumab | 18 Years - | University of Arizona | |
| Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) | NCT02277197 | Carcinoma, Squa... Squamous Cell C... Squamous Cell C... | Ficlatuzumab Cetuximab | 18 Years - | University of Pittsburgh | |
| Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma | NCT02277184 | Carcinoma, Squa... | Ficlatuzumab Cisplatin Intensity Modul... | 18 Years - | University of Pittsburgh | |
| A Study of Ficlatuzumab With HiDAC and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid Leukemia | NCT04100330 | Acute Myeloid L... | Ficlatuzumab Cytarabine | 18 Years - | AVEO Pharmaceuticals, Inc. | |
| Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient | NCT02090127 | Mullerian Mixed... | ficlatuzumab | 18 Years - | AVEO Pharmaceuticals, Inc. | |
| Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML | NCT02109627 | Acute Myeloid L... Relapsed Acute ... Refractory Acut... | Ficlatuzumab Cytarabine | 18 Years - | University of California, San Francisco | |
| Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer | NCT03316599 | Pancreatic Canc... | Gemcitabine Nab-paclitaxel Ficlatuzumab | 18 Years - | Dana-Farber Cancer Institute | |
| Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma | NCT02277184 | Carcinoma, Squa... | Ficlatuzumab Cisplatin Intensity Modul... | 18 Years - | University of Pittsburgh | |
| A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma | NCT06064877 | Metastatic Head... Recurrent Head ... | Ficlatuzumab Cetuximab Placebo | 18 Years - | AVEO Pharmaceuticals, Inc. | |
| Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma | NCT03422536 | Head and Neck B... Recurrent Head ... Recurrent Oroph... Squamous Cell C... Stage IV Squamo... Stage IV Squamo... Stage IV Nasoph... Stage IV Oropha... Stage IVA Lip a... Stage IVA Nasal... Stage IVA Nasop... Stage IVA Oroph... Stage IVB Lip a... Stage IVB Nasal... Stage IVB Nasop... Stage IVB Oroph... Stage IVC Lip a... Stage IVC Nasal... Stage IVC Nasop... Stage IVC Oroph... Head and Neck C... Oropharyngeal C... HNSCC Stage IV Lip an... | Cetuximab Ficlatuzumab | 18 Years - | University of Arizona |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
